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Frequently Used Terms 
 
Adherence In medicine, compliance (also adherence) describes the 
degree to which a patient correctly follows medical advice. 
Most commonly, it refers 
to medication or drug compliance, but it can also apply to 
other situations such as medical device use, self-care, self-
directed exercises, or therapy sessions. 
PCRS  Primary Care Reimbursement Service 
GMS General Medical Service 
DPS Drug Payment Scheme 
LTI Long Term Illness Scheme 
HT High Tech distribution  
OPD Obstructive Pulmonary Disorder 
 
Respiratory Drugs 
 
Indication 
 
Salbutamol  
 
Indicated for the treatment or prevention of bronchospasm. 
It provides short acting bronchodilation in reversible 
airways obstruction due to asthma and chronic obstructive 
pulmonary disease (COPD) such as chronic bronchitis and 
emphysema. 
Beclometasone Indicated for the Prophylactic management in: Mild 
asthma (PEF values greater than 80% predicted at baseline 
with less than 20% variability): Patients requiring 
intermittent symptomatic bronchodilator asthma 
medication on more than an occasional basis. 
Moderate asthma (PEF values 60 - 80% predicted at 
baseline with 20 - 30% variability): Patients requiring 
regular asthma medication and patients with unstable or 
worsening asthma on other prophylactic therapy or 
iv 
 
bronchodilator alone. Severe asthma (PEF values less than 
60% predicted at baseline with greater than 30% 
variability): Patients with severe chronic asthma. 
Salmerterol  
& other drugs 
 
Asthma: The regular treatment of asthma where use of a 
combination product (long-acting β2 agonist and inhaled 
corticosteroid) is appropriate Chronic Obstructive 
Pulmonary Disease (COPD): indicated for the 
symptomatic treatment of patients with COPD, with a 
FEV1 <60% predicted normal (pre-bronchodilator) and a 
history of repeated exacerbations, who have significant 
symptoms despite regular bronchodilator therapy. 
Salbutamol  
& other drugs  
 
As above in combination. 
Carbocisteine 
 
Indicated for the adjunctive therapy of respiratory tract 
disorders characterised by excessive or viscous mucus. 
Tiotropium bromide Indicated as a maintenance bronchodilator treatment to 
relieve symptoms of patients with chronic obstructive 
pulmonary disease (COPD). 
Formoterol  
& other drugs  
 
Indicated for Prophylaxis and treatment of 
bronchoconstriction in patients with asthma as an add-on 
to inhaled corticosteroid (ICS) treatment. 
Prophylaxis of bronchospasm induced by inhaled 
allergens, cold air or exercise. Prophylaxis and treatment 
of bronchoconstriction in patients with reversible or 
irreversible chronic obstructive pulmonary disease 
(COPD) including chronic bronchitis and emphysema. 
Montelukast 
 
Indicated in the treatment of asthma as add-on therapy in 
those patients with mild to moderate persistent asthma 
who are inadequately controlled on inhaled corticosteroids 
and in whom “as-needed” short acting beta-agonists 
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provide inadequate clinical control of asthma. In those 
asthmatic patients in whom Montelukast is indicated in 
asthma, it can also provide symptomatic relief of seasonal 
allergic rhinitis.  
Montelukast is also indicated in the prophylaxis of asthma 
in which the predominant component is exercise-induced 
bronchoconstriction. 
Fluticasone nasal Indicated in adults, adolescents and children (6 years and 
over) for the treatment of the symptoms of allergic rhinitis. 
Mometasone Indicated in adults and adolescents 12 years of age and 
older for regular treatment to control persistent asthma. 
Fluticasone inhaled Asthma: Fluticasone propionate has a marked anti-
inflammatory effect in the lungs. It reduces symptoms and 
exacerbations of asthma in patients previously treated with 
bronchodilator alone or with other prophylactic therapy. In 
the majority of patients it has no effect on adrenal function 
or reserve at the recommended doses. Severe asthma 
requires regular medical assessment as death may occur. 
Patients with severe asthma have constant symptoms and 
frequent exacerbations, with limited physical capacity, and 
PEF values below 60% predicted at baseline with greater 
than 30% variability, usually not returning entirely to 
normal after a bronchodilator. These patients will require 
high dose inhaled (see dosage instructions) or oral 
corticosteroid therapy. Sudden worsening of symptoms 
may require increased corticosteroid dosage which should 
be administered under urgent medical supervision.  
vi 
 
Sildenafil Indicated for the treatment of adult patients (≥ 18 years) 
with pulmonary arterial hypertension who are currently 
prescribed oral Revatio and who are temporarily unable to 
take oral therapy, but are otherwise clinically and 
haemodynamically stable. The oral formulation is 
indicated for treatment of adult patients with pulmonary 
arterial hypertension classified as WHO functional class II 
and III, to improve exercise capacity. Efficacy has been 
shown in primary pulmonary hypertension and pulmonary 
hypertension associated with connective tissue disease. 
Tadalafil  
 
Indicated in adults for the treatment of pulmonary arterial 
hypertension (PAH) classified as WHO functional class II 
and III, to improve exercise capacity. 
Bosentan Indicated for treatment of pulmonary arterial hypertension 
(PAH) to improve exercise capacity and symptoms in 
patients with WHO functional class III. Efficacy has been 
shown in: Primary (idiopathic and heritable) pulmonary 
arterial hypertension. Pulmonary arterial hypertension 
secondary to scleroderma without significant interstitial 
pulmonary disease. Pulmonary arterial hypertension 
associated with congenital systemic-to-pulmonary shunts 
and Eisenmenger's physiology. 
Iloprost Indicated for Treatment of adult patients with primary 
pulmonary hypertension, classified as NYHA functional 
class III, to improve exercise capacity and symptoms. 
vii 
 
Tobramycin  
 
Indicated for management of chronic pulmonary infection 
due to Pseudomonas aeruginosa in patients with cystic 
fibrosis aged 6 years and older. 
Palivizumab  
 
Indicated for the prevention of serious lower respiratory 
tract disease requiring hospitalisation caused by 
respiratory syncytial virus (RSV) in children at high risk 
for RSV disease: Children born at 35 weeks of gestation 
or less and less than 6 months of age at the onset of the 
RSV season. Children less than 2 years of age and 
requiring treatment for bronchopulmonary dysplasia 
within the last 6 months. Children less than 2 years of age 
and with haemodynamically significant congenital heart 
disease. 
Ambrisentan 
 
Indicated for treatment of pulmonary arterial hypertension 
(PAH) in adult patients of WHO Functional Class (FC) II 
to III, including use in combination treatment. Efficacy has 
been shown in idiopathic PAH (IPAH) and in PAH 
associated with connective tissue disease 
Ivacaftor Indicated for the treatment of patients with cystic fibrosis 
(CF) aged 18 years and older who have 
an R117H mutation in the CFTR gene 
Pirfenidone Indicated in adults for the treatment of mild to moderate 
Idiopathic Pulmonary Fibrosis (IPF). 
Aztreonam Indicated for Lower respiratory tract infections: including 
pneumonia, bronchitis and lung infections in patients with 
cystic fibrosis. 
 
 
 
 
 
Executive Summary  
viii 
 
Respiratory disease, is part of the Governments chronic disease management policy. 
The aim is to manage chronic disease patients as close to their home for as long as 
possible. The economic benefit of this is to improve medicine adherence and avoid the 
cost of emergency hospital admissions. One adherence barrier is cost of medicines.  
The aim of this report was to gain clarity on respiratory medicines expenditure for an 
eleven year period from 2005-2015. Findings showed that expenditure on all 
medicines have been decreasing in recent years, with 2015 figures being less than 
expenditure in 2006. Respiratory medicines have been less than 10% of total 
medicines expenditure in the PCRS during this time. Drugs for OPD are the most 
frequently prescribed and highest expenditure medicine class.  B2 stimulants are the 
most frequently prescribed drug group and B2 stimulants and corticoids have the 
highest expenditure.87% of drugs to treat OPD are dispensed publicly and 13% 
privately. A scenario analysis estimated that the extra cost to the State ranged between 
€20.2m to €33.8m, to provide respiratory medicines through public schemes, thus 
removing a barrier to adherence. By improving adherence rates the department is 
providing best outcomes and use of its finite resources 
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Section 1.  Introduction 
In 2016, total Government expenditure was €55 billion of which €18 billion (24% of 
total expenditure) was spent in health1. There is a finite financial resource that can be 
allocated to the provision of healthcare. However, there is an increasing need to access 
this derived demand. People want to be healthy and in order to achieve it they have to 
access the health care system at different stages, whether for services of a health care 
professional or medicines.  One factor that contributes to this demand is a rapidly aging 
population. Currently there are 540,000 people aged 65+ in Ireland, 12% of the total 
population. This is set to rise to 22%, by 2041 2.  When one gets older, there is often 
more need to access health care due to the fact that inevitably there can be a higher 
frequency of ill health. Society wants to live longer, but it also wants that those years 
gained are lived in as much good health as possible. Considering aging as just one 
contributing factor, one can see that societies demand for health care can be unlimited.  
 
Health care as a resource is therefore finite and has to be managed effectively, even 
more so in recent years with the effect the bailout and recession has had on reducing 
budgets. The reality of this has resulted in tighter regulation on funding and monitoring 
of expenditure in all sectors including health. From an economic perspective, the more 
clarity there is on expenditure of public and private funds, the better informed the State 
is on deciding which initiatives or medicines to invest in now so as to offset the future 
costs to the health service.  
 
This report examines expenditure of medicines to treat respiratory disease. Respiratory 
disease is made up of a large number of smaller diseases that can affect a person. One 
of them is asthma, another is chronic obstructive pulmonary disease, and the State has 
implemented programmes to enable the management of these diseases outside the 
hospital. An example of one initiative they have introduced, in order to alleviate 
pressure (both financial and capacity) on the health care system in hospitals, are 
chronic disease management programmes 3. This is where patients who have certain 
chronic diseases, are managed in the community. This satisfies the patients demand 
for health care and ultimately offsets the financial pressure on the State by aiming to 
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improve adherence to medicines to avoid future events including admissions to 
hospital. Cost of medicines is one barrier to adherence.  
 
The aim of this report is to conduct an eleven year review of respiratory medicine 
expenditure in Ireland from 2005-2015 and to calculate an estimated cost for the State 
to cover the total cost of respiratory medicines through public schemes such as the 
LTI. Thus the State would be removing another barrier to adherence. By improving 
adherence rates the Government is aligning with its policy of chronic disease 
management programme, providing best outcomes for patients and best use of its finite 
resources. 
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Section 2.  Background and Approach 
The effects of the economic crisis that hit Ireland in 2008 are now abating and nearly 
ten years later the people of Ireland are beginning to feel confidence of coming out of 
a severe crisis and ongoing recession. Tight monitoring and control of expenditure on 
a national level has to remain in order to be able to manage the public finances well. 
In 2016, total Government expenditure was €55 billion of which €18 billion was spent 
in health. This was approximately 24% of total expenditure, second only to social 
protection which spent 36% of the budget1. Due to the fact that health is such a large 
proportion of total Government expenditure it is critical for the nation that this 
department controls its expenditure and manages the budget it receives most cost 
effectively. The Health budget of €18 billion contains all expenditure, including 
capital and pay and pensions etc. it also includes expenditure on medicines. The focus 
of this report is on expenditure of medicines (respiratory in particular) through the 
public schemes over an eleven year review period. 
Healthcare in Ireland is managed under a two tier system of funding. 78.3% is funded 
by the Government through general taxation and the remainder is funded privately. 
Approximately half the population use the public system and half also purchase health 
insurance 4. The Health Services Executive (HSE) controls both budget and services 
for the public funded sector. The HSE pays the primary care or community setting 
services via the Primary Care Reimbursement Service (PCRS). There are over 7,100 
primary care contractors and a range of community health schemes22.The schemes 
form the infrastructure through which the Irish Health System delivers a significant 
proportion of Primary Care to the public. The community health schemes that are the 
focus of this report are the General Medical Services (GMS), the Drug Payments 
Scheme (DPS) the Long Term Illness Scheme (LTI) and the High Tech Arrangement 
(HT). These are described in more detail in the appendices, table 1. If a patient does 
not fulfil the criteria for public reimbursement discussed above they pay themselves 
privately.  
Though there is a finite resource allocated to health care, there is an unlimited demand 
for it. One factor that contributes to this unlimited demand is a rapidly aging 
population. In Ireland by 2041, there will be 1.4 million aged 65 and over (22% of the 
population) 2. Part of the aging process is the development of chronic diseases. Chronic 
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diseases are long-term, life-limiting conditions which can be treated and controlled 
but not cured. 38% of the Irish population report that they have a chronic disease and 
over half of people over 50 have at least one chronic disease 5. This rises to 62% in 
the over 65 category5. Chronic diseases are responsible for about 60% of deaths 
worldwide and 76% of deaths in Ireland 5. 4 out of 10 hospitalisations in Ireland in 
2011 were either directly or indirectly due to the four of the main chronic diseases - 
cancer, cardiovascular disease, respiratory disease and diabetes 5.40% of the adult 
population in Ireland will have one or more chronic diseases by 20205. Having a 
chronic disease means that it has to be managed on an ongoing basis, thus one can see 
that both the increase in an aging population and an increase in chronic diseases will 
continue to contribute to the demand for healthcare. This (health care) is a derived 
demand. The demand is for people to have good health and this is brought about 
through accessing healthcare to maintain that good health.  
Taking into account that there is an unlimited demand for health care it then follows 
that decisions have to be made on how to allocate finite resources, both budget and 
services, in order to provide the best outcomes for the nation for a healthy active old 
age. In order to be able to achieve this, the way chronic disease, is managed is an 
important contributing factor. One aspect of having a chronic disease is that adherence 
to medications can be low 6. The State has considered this problem and has developed 
policies to overcome one of the adherence barriers which is access to medicines and 
treatments. They have initiated integrated care programmes for prevention and 
management of chronic disease. The aim of which is to provide care and support as 
close to home as is required, thereby facilitating the access to medications and 
treatments for the patients with the result that adherence will increase. If this occurs it 
will result in best health outcomes, enhanced clinical decision making and the most 
effective use of resources 7.   
Irish research shows that there are several factors for a low adherence rate one of which 
is access to medications and treatments and another is cost of medications. It found 
that there were higher adherence rates in those who were on medical cards than those 
that had to pay or co-pay themselves8. This is following the economic law of demand 
which states that as the price of medicines increases the quantity of demand for 
medicines decreases ceteris paribus. Correspondingly, if the price of medicines 
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decreases (from the patients perspective) the demand for the medicine increases. If the 
law of demand were to be followed this could lead to removing another adherence 
barrier and increasing adherence rates. The State could remove the cost of medicines 
to the patient by paying for any not covered by an existing PCRS scheme on the LTI.  
From an economic perspective, the benefit of these programmes is that by closely 
managing patients in their community, this will lead to increased adherence to their 
medicines and improved compliance with disease management programmes 9. This 
improvement in management of chronic disease can be offset against reduced 
admittance to hospital and reduced costs of more expensive crisis management of 
patients.  
Respiratory disease, including asthma and pulmonary disease, are one of the main 
chronic diseases that the Government is aiming to shift from hospital to primary care 
management, through this programme and includes the national programme for 
asthma 9. Respiratory medicine is concerned with the treatment of 30 respiratory and 
related conditions. At present lung disease causes one in five deaths in Ireland and is 
the third most common reason for emergency hospital admission 9 There are also 
upward trends in the prevalence of asthma, interstitial lung disease and sleep disorders. 
Respiratory diseases are therefore likely to remain a major burden on European 
societies for decades to come9.  In Ireland there were 3,438 deaths from diseases of 
the respiratory system in 2011 of which 1,625 were males and 1,813 were females. 
Diseases of the respiratory system accounted for 12.1% of all deaths (0.75 per 1,000 
of population), affecting, in particular, the older age groups, with 79.3% of these 
occurring in persons aged 75 and over. These were largely made up of 1,504 deaths 
from chronic lower respiratory diseases and 1,062 deaths due to pneumonia (which 
often accompanies COPD), which combined accounted for 75% of respiratory deaths 
9. Asthma in particular is a respiratory disease that is characterised, in Ireland, by high 
disease prevalence, suboptimal control in the majority of patients, low uptake of 
objective lung function tests for diagnosis and management, infrequent use of asthma 
management plans and poor patient education10. Ireland has the fourth highest 
prevalence of asthma world-wide, affecting an estimated 450,000 people. At least one 
person dies from asthma every week in Ireland10. The Global Initiative for Asthma 
(GINA) guidelines provides recommendations for the diagnosis and management of 
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asthma in patients aged 5 years and older, in the primary care setting and is a core 
component of the national asthma programme. The scope of the national asthma 
programme is to ensure the management of asthma is based on current international 
evidence-based care in all care settings including primary care. The aim of the 
programme is to reduce morbidity and mortality associated with asthma in Ireland and 
to improve the quality of life for all patients with asthma 10.  
The impact of old age and chronic disease, in particular respiratory disease, in Ireland 
is large and has major implications to where the health care budget has had to have 
been spent. Thus we can see the importance from an economic perspective, of 
implementing Government policy and instigating an integrated chronic disease 
management programme for respiratory diseases such as asthma and COPD.  The 
financial benefits of improved adherence with medicines and compliance with 
management of the chronic disease coupled with the discounted costs of reduced 
admittance to hospital and emergency medicine management are compelling for a 
department that have to manage this finite resource.  
The focus of this report is to review respiratory medicines expenditure from 2005-
2015 in order to be able to provide information on the cost of medicines in respiratory 
disease. In particular, to gain clarity on public and private spend in respiratory 
medicines, in order to calculate how much it would cost the State to cover all costs on 
respiratory medicines. If this was the case another adherence barrier, the cost of 
medicines to the patient, would be removed. This could result in increasing adherence 
and improving outcomes.   
The idea for this report originated from Irish research on respiratory disease in Ireland 
(2003 and 2008).  The INHALE report describes in depth the management of 
respiratory disease in Ireland. Brennan et al stated that they have “provided a 
benchmark for tracking changes and assessing trends in the mortality, morbidity and 
treatment of respiratory disease” 11.The second edition had amongst its report the 
following updates from the first edition: Comparisons with other countries and other 
diseases reveal that Ireland’s record in tackling lung disease, rather than improving, 
has in fact fallen behind. Respiratory disease still causes one in five deaths in Ireland. 
Death rates from respiratory disease are almost twice the EU average. Lung cancer is 
7 
    
still the biggest cancer killer in Ireland. Statistics on the prevalence and cost of 
respiratory disease show a similarly bleak picture: Respiratory disease is still among 
the most commonly reported long-term illnesses in young adults. Respiratory diseases 
are still the most common reason to visit a GP and the third most common reason for 
acute admission to hospital. Drug prescriptions for respiratory disease are amongst the 
highest for any organ system. Prevalence of asthma, the most common chronic 
childhood disease, is rising. The authors commented that, “Increased resources to 
better manage the disease are required if this trend is to be reversed” 11.   The second 
edition of INHALE was published in 2008 and from this we can see that respiratory 
disease affects a large number of people in Ireland and how it is managed is important 
to provide the best outcomes for these patients in a setting as close to their home as 
possible.  The purposes of the research undertaken here is to aid the information in this 
area. It follows on in part from INHALE by re-examining subsections of the INHALE 
report, such as expenditure on vaccinations for prevention of respiratory disease and 
expenditure in the PCRS on respiratory medicines. The aim of this report is to provide 
clarity on how much has been spent on medicines to treat respiratory disease in the 
primary care setting for the period that has been reviewed, 2005-2015. From this 
information trends will enable predictions and assumptions to be made on future 
expenditure on respiratory medicines in the primary care setting. It will also ascertain 
what proportion and how much has been spent on respiratory through the PCRS and 
privately. Finally, this report goes on to estimate the cost to the State if all respiratory 
medicines were included in LTI public scheme. If all respiratory medicines were paid 
via public schemes one more barrier to adherence of medications would be removed. 
This could increase adherence to medicines and align with Government policy of 
management of integrated care, chronic disease programmes for respiratory disease. 
The result of this could be to provide best outcomes for patients and best use of the 
departments finite resources. 
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Section 3.  Methodology 
Government policy is to implement integrated chronic disease management 
programmes. Resulting in best health outcomes, enhanced clinical 
decision making and the most effective use of resources7. From an economist 
perspective, the theory behind these programmes is that by increasing adherence to 
medicines and compliance to management of the chronic disease in the community 
will result in less expenditure in admittance to hospital and crisis management. Thus 
making most effective use of finite resources. Respiratory disease is part of the chronic 
disease management programme. One barrier to adherence is the cost of medicines. 
The aim of this report is to providing clarity on respiratory medicines expenditure by 
firstly conducting an eleven year review of respiratory medicine expenditure in Ireland 
from 2005-2015 and secondly to estimate the cost for the Government to pay for all 
respiratory medicines through PCRS. Thus removing an adherence barrier. Two data 
sets were used to conduct this univariate analysis. The first was the data from the 
published Primary Care Reimbursement Services (PCRS) statistical analysis reports 
and the second was data supplied by QuintilesIMS Ltd.  
3.1.   Data. 
3.1.1. Primary Care Reimbursement Services (PCRS). 
For the purposes of this research, the PCRS Schemes that are involved in patients that 
use respiratory medicines have been analysed over an eleven year period from 2005 
to 2015.  These schemes include the General Medical Card Scheme (GMS), The Drug 
Payments Scheme (DPS) the Long term Illness Scheme (LTI) and the Hi Tech 
Reimbursement Process (HTD). The HSE publishes a report detailing what has been 
spent in each scheme annually. It also publishes how frequently each preparation has 
been prescribed within each scheme. A detailed statistical analysis on the schemes 
involved in the PCRS is also published in this annual report. 
The data for this analysis has been extracted from the following sections in the PCRS 
report for each year from 2005 to 2015 12-22. 
i) Total Spend of Major Therapeutic Classification of Drugs, Medicines and 
Appliances for: 
-The General Medical Services Scheme (GMS)  
-The Drug Payments Scheme (DPS) and  
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-The Long Term illness Scheme (LTI) 
ii) Summary Statement of Activity during Year: Total Payments to 
Wholesalers under the Hi Tech Drugs Reimbursement Process (HTD). 
Once the data was identified, for the eleven year review period, this was tabulated into 
both tables and graphs in order to be able to describe the data and draw conclusions 
from it. 
3.1.2. QuintilesIMS Ltd Drugs for obstructive pulmonary disorder medicines 
data. 
QuintilesIMS Ltd is a company that provides insights and data on different therapeutic 
areas to its client base. For the purposes of this research QuintilesIMS Ltd has made 
available the respiratory medicines data section, for the eleven year period that is being 
reviewed in this research. It comprises of two data sets, the first is the sell-in data for 
respiratory medicines23. This comprises of data on drugs that are used to treat 
obstructive pulmonary disease (OPD). It encompasses all pharmacies, either hospital 
or community. The data range is from 2005 to 2015. It supports the PCRS data and 
allows for in depth analysis to be carried out that enables the objectives of this research 
to be met. This data was extracted, tabulated and graphed in order to be able to 
compare and draw conclusions from it. 
The second set of data that has been provided from QuintilesIMS Ltd is the sell-out 
data for respiratory medicines23. This is information identifying which scheme the 
medicine that is being dispensed from the pharmacy has been allocated to. The scheme 
will either be a Government scheme that comes under the PCRS review and will be 
either GMS, DPS, or LTI. The other option will be a private allocation which is funded 
by the individual patient. This data has been available since July 2014 and the review 
for this data set takes place from then until June 2016. The data set that has been 
provided is for respiratory medicines, in particular drugs for OPD. Using this data 
enables the final two objectives of this research to be able to be met by calculating the 
percentage allocation per scheme, and how much extra the Government would need 
to spend in order to cover the total cost of respiratory medicines to the public. 
3.2. Data analysis methods. 
From these two sets of data a univariate analysis was conducted to meet the aim of 
this research. The data analysis is structured in accordance to the four objectives of 
10 
    
the research. The first objective was to review expenditure on all PCRS medicines 
from 2005-2015. The PCRS data was used to achieve this objective. The statistical 
analysis reports from 2005-2015 were reviewed and the data extracted to tabulate this 
information. Graphs then illustrate the eleven year trend.  
The second objective was to review expenditure on all respiratory medicine in the 
PCRS from 2005-2015. The statistical analysis reports and QuintilesIMS Ltd data 
were used. This is a large objective which is multi layered. Therefore this objective 
was subdivided further and an in-depth analysis was undertaken to review the 
following: 
1)  Compare PCRS expenditure on respiratory medicine to total expenditure. 
2)  Identify most frequently prescribed and highest expenditure respiratory 
medicine class. 
3) Identify most frequently prescribed and highest expenditure drug class. 
4) Review spend on prevention of respiratory disease. 
The third objective used QuintilesIMS Ltd data to estimate what percentage of 
expenditure on respiratory medicines is privately funded.  
The fourth objective is to calculate how much the Government would have to spend 
in order to cover the costs of respiratory medicines for all patients. This was 
determined by using the percentage calculated in objective three with the total public 
expenditure for respiratory medicines identified in the PCRS data. The private 
expenditure will also be identified in actual and percentage terms. This private amount 
is not currently covered by the Government and is the amount the Government would 
have to spend in order to cover the costs of respiratory medicines for all patients. 
By completing these four objectives the aim of the research paper will have been 
achieved. 
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Section 4.  Findings and Recommendations 
4.1.  Objective 1: Expenditure on all PCRS medicines from 2005 – 2015. 
Table 2 and Graph 1 documents the total spend in the PCRS from the years 2005-
2015.  The total cost has increased from €1,320 million in 2005 to €1,399.65 million 
in 2015. The highest spend occurred in 2009 with a total spend on €1,851.72 million. 
Since 2009, there have been reductions in values to the extent that the 2015 amount is 
lower than 2006 expenditure. 
 
Table 2: Total Spend of Major Therapeutic Classification of Drugs Medicines and 
Appliances. 2005-2014 PCRS schemes. 
 
YEAR GMS  
€M 
DPS 
 €M 
LTI 
 €M 
TOTAL 
 €M 
HTD 
€M* 
2005 831.44 388.02 100.54 1,320.00 168.76 
2006 940.22 422.92 115.46 1,478.60 207.25 
2007 1,048.40 491.19 124.46 1,664.05 238.51 
2008 1,145.29 506.81 137.90 1,790.00 275.39 
2009 1,260.25 451.71 139.76 1,851.72 315.36 
2010 1,233.27 336.02 126.92 1,696.21 345.76 
2011 1,207.34 277.50 118.10 1,602.94 350.18 
2012 1,288.82 254.51 117.10 1,660.43 385.04 
2013 1,222.21 189.43 106.51 1,518.15 442.27 
2014 1,118.94 156.27 139.19 1,414.40 484.71 
2015 1,054.30 155.87 189.48 1,399.65 544.19 
 
Source: Primary Care Reimbursement Service (PCRS): Statistical Analysis of Claims and Reimbursements 2005-2015.GMS = 
General Medical Service; DPS=Drug Payment Scheme; LTI=Long Term Illness Scheme; HTD= Hi Tech Drugs Scheme *Data 
from Summary Statement Payments to Wholesalers under the HTD Scheme. 
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Graph 1. Total PCRS spend. 
 
 
Graph 2 depicts the individual PCRS scheme, GMS 12-22, DPS 12-22 and LTI 12-22 from 
2005-2015 which is documented in table 2. This graphs illustrates that there have been 
some fluctuations on a yearly basis between schemes. The largest allocation of budget 
has been to the GMS. The allocation on this scheme had been increasing on a continual 
basis from 2005 to 2009. However, in 2010 onwards it reduced to €1054.3m in 2015, 
which is less than 2008 values. The next largest scheme is the DPS scheme. Graph 2 
also illustrates that the DPS scheme has reduced in spend consistently since 2008. The 
LTI scheme, has had the least amount of budget allocated to it out of all of these PCRS 
schemes. Spend on the LTI has consistently been below €140m until 2015 where it 
increased to €189.48m. Expenditure on the Hi Tech (HTD) scheme 12-22, has risen 
consistently from €168.76m in 2005, to a total spend of €544.19m in 2015, as shown 
in graph 3. 
In summary, total PCRS expenditure on all medicines have been decreasing in recent 
years with 2015 figures being less than expenditure in 2006. Most expenditure is on 
the GMS scheme followed by the DPS and LTI. The HTD has risen in expenditure to 
€544.19m in 2015. 
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Graph 2. Total spend by PCRS scheme. 
 
 
Graph 3. Payments to Wholesalers under the HTD. 2005-2015. 
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4.2.  Objective 2: To review expenditure on all respiratory medicine in the 
PCRS from 2005 – 2015. 
4.2.1.  PCRS expenditure on respiratory medicine in comparison to total 
expenditure. 
Table 3 and graph 4 illustrates that, similar to the PCRS total medicines expenditure, 
the combined PCRS expenditure on respiratory drugs had consistently risen on a 
yearly basis from 2005 to 2009. Expenditure then decreased to €135.25m in 2015 this 
is approximately 2006 respiratory medicine expenditure.    
 Graph 4. Total PCRS Respiratory Spend 2005 - 2015. 
 
Total respiratory medicines expenditure has always been below 10% of total PCRS 
spend (graph 5). However, in 2015 there has been an increase from the 2009 (the 
highest year of respiratory medicine expenditure) 9.1% up to 9.66%. Thus reflecting 
that though the total respiratory medicine actual expenditure has decreased over the 
review period, it has not decreased as much as the total medicines expenditure in the 
PCRS.  
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Graph 5. Total PCRS Scheme spend v Total Respiratory PCRS scheme spend. 2005-
2015. 
 
 
Table 3: 2005-2015 PCRS Schemes: Total Spend of Major Therapeutic Classification 
of Drugs, Medicines and Appliances.  Respiratory. 
Source: Primary Care Reimbursement Service (PCRS): Statistical Analysis of Claims and Reimbursements 2005-2015.GMS 
=General Medical Service; DPS=Drug Payment Scheme; LTI=Long Term Illness Scheme; RESP = Respiratory 
0.00
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€
m
TOTAL
RESP 
SPEND/SCHEME*
GMS + DPS + LTI
€M
TOTAL
€M
YEAR  RESP  
SPEND  
GMS 
€M 
RESP  
SPEND 
AS % OF 
TOTAL  
GMS 
SPEND 
RESP 
SPEND 
DPS 
€M 
RESP 
SPEND 
AS % 
OF 
TOTAL 
DPS 
SPEND 
RESP 
SPEND 
LTI 
€M 
RESP 
SPEND 
AS % 
OF 
TOTAL 
LTI 
SPEND 
TOTAL 
RESP  
SPEND/ 
SCHEME* 
GMS + 
DPS + LTI 
€M 
TOTAL 
RESP 
SPEND/ 
SCHEME 
AS % OF 
TOTAL 
SPEND/ 
SCHEME 
2005 74.44 8.95 44.58 11.49 0.53 0.53 119.55 9.06 
2006 83.93 8.93 49.90 11.27 0.59 0.51 134.42 9.09 
2007 94.29 8.99 54.64 11.13 0.63 0.51 149.56 8.99 
2008 102.45 8.95 55.83 11.02 0.67 0.49 158.95 8.88 
2009 117.19 9.30 50.67 11.22 0.67 0.48 168.53 9.10 
2010 115.01 9.33 38.12 11.35 0.49 0.39 153.62 9.06 
2011 113.35 9.39 33.44 12.05 0.43 0.37 147.22 9.18 
2012 120.91 9.38 30.57 12.01 0.44 0.38 151.92 9.15 
2013 114.81 9.39 22.69 11.98 0.41 0.39 137.91 9.08 
2014 112.85 10.09 18.94 12.12 0.51 0.37 132.30 9.35 
2015 115.47 10.95 19.20 12.32 0.58 0.31 135.25 9.66 
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To understand how this increase in 2015 has come about, further analysis was 
conducted to examine how the total respiratory spend was allocated into the different 
PCRS schemes.  In table 3 and graph 6 GMS allocated respiratory medicines show a 
consistent increase from 2005-2009, thereafter the values decreased with the exception 
of 2012 onwards. This data was then analysed in percentage terms and despite the 
reduction of actual spend on respiratory drugs in recent years, expenditure has 
increased in percentage terms from 8.95% in 2005 to 10.95% in 2015.  In the DPS, 
from 2009 onwards there is a decrease in actual spend on respiratory medicines but in 
percentage terms the expenditure has increased from 11.49% in 2005 to 12.32% in 
2015.  The only scheme that has decreased in percentage terms is the LTI scheme. 
This has decreased from 0.53% 2005 to 0.31% in 2015. Illustrating how few 
respiratory drugs on this scheme. The GMS is the largest public scheme in primary 
care and this is followed by the DPS, therefore any fluctuations seen in either of these 
schemes, but in particular the GMS, will have an impact on the total value. Which has 
been the case for respiratory medicine in 2015. 
Graph 6: Respiratory spend per PCRS scheme. 2005-2015. 
 
In summary, in this review, total respiratory medicines expenditure has always been 
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decreased in expenditure it has not decreased as much as the expenditure on total 
medicines. What this means is that the proportion of expenditure has increased on 
respiratory medicines in this time frame. From a percentage aspect, the GMS and DPS 
has increased expenditure in respiratory medicines in 2015. As the GMS and DPS are 
the largest schemes in the PCRS this impacts on the total respiratory medicine 
expenditure in the PCRS. 
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4.2.2.  Most frequently prescribed and highest expenditure respiratory 
medicine class.  
All medicines including respiratory medicines are classified into a number of different 
Anatomical Therapeutic Classification (ATC) groups, by the World Health 
Organisation (WHO) 24. There are 7 ATC classification for respiratory medicines. 
They are: 
a) Drugs for obstructive pulmonary disorder(OPD) 
b) Nasal Preparations 
c) Antihistamines systemic use 
d)  Inhaled mucolytics 
e) Cough and cold preparations 
f) Throat preparations 
g) Other Respiratory preparations 
 Using the data from the PCRS reports 12-22, Graph 7 and table 4 a and b in appendix 
i) presents the ten year ingredient cost per scheme of respiratory medicines according 
to ATC group. It shows that the most spend by far was in the drugs for obstructive 
pulmonary disorder (OPD) drugs. This group contributed to the highest ingredient cost 
from all schemes for all years (2005-2015). The ingredient cost for OPD drugs for all 
schemes, consistently rose from €82m in 2005 to €120m in 2009 than decreased to 
€97.8m in 2015.  This 2015 value is less than 2007 expenditure on drugs for OPD on 
all schemes. There was much less expenditure for most of the other ATC classification 
groups. However, the same trend for expenditure was followed for most of these 
groups. Graph 7 illustrates the increase in expenditure from 2005-2009 for most 
groups then the subsequent decreases in expenditure to the 2015 value. The exception 
was the ‘other respiratory systems’ classification. This group has shown a sharp 
increase in cost since 2012. This sharp increase was only allocated to the HTD scheme 
and reflects the use of newly approved respiratory drugs that are only available on this 
scheme.  The expenditure on the HTD in 2015 is €33m and contributes largely to the 
increase in expenditure for the total respiratory medicines value of €142.36m in 2015.  
To further support this, table 4 is an analysis of the respiratory ATC groups by scheme. 
The GMS (the largest scheme) 2015 value is less than 2009 expenditure. Whilst the 
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DPS 2015 value is less than the 2005 expenditure. HTD on the other hand has 
increased from 0 expenditure in 2005, when it was introduced, to €25.5m in 2013 and 
€34.13m in 2015 in the respiratory medicines category.  
Graph 7. ATC Respiratory Ingredient cost per scheme. 2005-2015. 
 
 
 
Table 5 (appendix (i)) examines the prescribing frequency per scheme of the 
respiratory products according to ATC group. Prescribing frequency tracks, how often 
a drug is being prescribed by a healthcare professional.  If a medicine class is being 
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prescribed more, it is being used more to treat conditions and it will have an impact 
on expenditure allocated to the class. Drugs for OPD were prescribed most frequently 
in comparison to other preparations for treating respiratory disease. It can also be seen 
in graph 7 and tables 4 and 5 that the HTD, for respiratory medicines prescribing 
frequency and ingredient cost, have increased from 0, when it was introduced in 2005 
to €34.13m (7972 prescriptions) in 2015. A relatively small number of prescriptions 
have been dispensed but there is a large ingredient cost associated with this scheme, 
indicating a large individual cost per item. 
In summary, drugs for OPD, for this time range were the most frequently prescribed 
class and also the highest expenditure was allocated to this group of respiratory drugs. 
This indicates that on reviewing the respiratory ATC groups of medicines, drugs for 
OPD are the most commonly used to treat respiratory disease. 
 
4.2.3. Highest expenditure and most frequently prescribed drug class. 
QuintilesIms Ltd sell-in data23 was used in this analysis of highest expenditure and 
most frequently prescribed drug class. The sell in data is data that is received on orders 
of medicines from pharmacies. The pharmacists place orders from prescriptions that 
have been written by healthcare professional prescribers. The orders are forwarded to 
drug wholesalers and when they receive the order they can then distribute the required 
medicine to the pharmacy that has requested it23. This sell-in data informs only on 
what has been ordered by pharmacies and not what happens to it after it has been 
dispensed from pharmacies to the patient.  The most frequently used respiratory 
medicine ATC group is the drugs for OPD. A further analysis of the drugs to treat 
OPD was conducted to ascertain which was the most frequently prescribed and which 
had the highest expenditure. The drug classes that are used to treat OPD are: 
a. B2 stimulants and corticoids 
b. Anticholinergic and B2 stimulants 
c. Corticoids  
d. B2 Stimulants  
e. Antileuk, anti-asthmatics 
f. Xanthines 
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g. Nonsteroidal anti-inflammatories 
h. PDE4 inhibitors 
i. All other anti-asthmatics. 
Graph 8 shows the expenditure of each drug for OPD class for 2005 and contrasts with 
2014. B2 stimulants and corticoids have the highest expenditure. They have increased 
from €34.9m in 2005 to €55.9m in 2015 .This is followed by anticholinergic B2 
stimulants and then by corticoids alone.  
 
 
Graph 8: Respiratory medicine class comparison 2005 v 2015.  
 
In table 6, B2 stimulants and corticoids group had consistently the highest expenditure 
in the period. The highest was in 2012 at €61.5m that had reduced in 2015 to €55.9m. 
The next highest expenditure was the anticholinergic and B2 stimulants.  Since 2008 
approximately €20m per year has been spent by community pharmacies for this group 
of medicines. Corticoids have the third highest expenditure. There has been a decline 
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in this class since 2005 when €18 million was spent in comparison to 2015,when this 
had reduced to  €11million. B2 stimulants reflect a variable  but still consistent buying 
pattern, where the community pharmacy spent between  €8-9m a year throughout the 
review period . The other drug classes have variable and small expenditure as seen in 
Table6. 
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Table 6: Respiratory drug class from drugs that treat OPD. 2005-2014. Expenditure in retail pharmacies. Euros. 
 
Source: QuintilesIMS data. Respiratory medicines distributed from wholesalers to pharmacies. 2005-2015. Euros. 
Drugs for OPD Class € 
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B2-STIMULANTS 8,954,521 8,704,204 8,897,762 8,713,832 9,343,429 8,708,990 8,789,502 9,629,269 8,914,776 8,830,082 8,899,047 
B2-
STIMULANTS+CORTICOIDS 34,939,525 40,788,273 46,833,508 52,516,060 58,977,610 60,025,903 59,400,367 61,467,965 56,677,502 55,776,955 55,905,811 
ANTICHOLINERGIC+B2-
STIMUL 15,226,846 17,618,171 19,963,189 21,819,383 22,435,171 21,236,599 20,927,340 21,004,476 20,608,822 22,117,861 19,383,348 
CORTICOIDS 18,183,174 17,975,646 17,835,211 17,220,734 16,881,228 15,542,203 14,131,818 14,041,053 12,167,642 11,304,611 11,614,440 
ANTILEUK ANTI-
ASTHMATICS 4,494,543 5,868,190 7,438,045 8,552,449 9,168,111 9,874,542 11,421,522 12,257,165 8,095,542 5,279,169 4,336,822 
XANTHINES 945,453 903,685 831,872 757,010 718,113 660,638 612,044 583,436 468,116 428,269 406,433 
N-STEROIDAL RESP A-
INFLAM 235,431 152,742 89,261 78,674 75,921 66,436 58,928 57,772 52,543 35,449 39,145 
PDE4 INHIB ASTHMA/COPD 0 0 0 0 0 0 0 0 0 32,972 45,418 
ALL OTH A-ASTHMA & 
COPD 1,192 4,547 6,726 6,857 1,049 1,713 1,263 5,297 3,253 2,017 3,801 
Total Drugs for OPD  82,980,686 92,015,458 101,895,575 109,665,000 117,600,633 116,117,024 115,342,783 119,046,433 106,988,196 103,807,386 100,634,264 
2
4
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The sell-out data 23 provided by QuintilesIMS Ltd provides the information on how 
frequently a drug class is prescribed. The sell-out data is collated by how it is dispensed 
from the community pharmacy to the scheme the patient is with 23. This scheme could 
be a Government run or public scheme such as the GMS, DPS or LTI schemes or the 
patient may be buying the medicine privately. This data is analysed by the drug groups 
that treat OPD. This data has been available from July 2014 onwards. Graph 9 depicts 
how the respiratory drug class is dispensed into a particular scheme.  The schemes 
have been categorised into five groups. They are; general medical and general medical 
scheme repeat, drug payment scheme, the long term illness scheme, other schemes and 
finally private prescriptions. This data is represented by units dispensed.  
 
Graph 9. Respiratory ATC Classification units per scheme. Jul 2014- Dec 2014. 
 
Graph 9, the B2 agonists are the most commonly dispensed units in all the schemes. It 
should be noted here that though the B2 agonists are the most frequently dispensed 
drug class, they do not have the highest expenditure as per table 6. This indicates that 
they are a low cost item on a per pack basis. This is followed by the B2 agonists and 
corticoid combinations, here the second highest dispensed but first in expenditure 
indicating a higher cost per pack than the B2 agonists, though this drug class is a 
combination of two active medications and not one. The next highest dispensed are 
the anticholinergic and B2 stimulants. The same trend can be seen (appendix ii) graphs 
10 and 11) for all time periods available.    
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In summary, the highest expenditure of drug groups that treat OPD by community 
pharmacies are the B2 stimulants and corticoids where in 2015 €55.9m had been spent. 
This group is the second highest most dispensed group. The second largest expenditure 
was in the drug group, anticholinergic and B2 stimulants, where €19.3m was spent in 
2015. The next largest   class were the corticoids where €11m was spent in 2015. 
However, the highest dispensed drug class to treat OPD are the B2 stimulants, which 
have a lower expenditure (€8.8m in 2015) indicating a lower cost per item.
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4.2.4.  Trends in prevention of respiratory disease. 
Prevention of respiratory disease can be undertaken by a person getting vaccinations 
such as the influenza and pneumococcal vaccinations and also by taking a nebuliser to 
prevent an incident from getting worse. Using data published In the PCRS reports 12-
22, analysis of certain respiratory disease prevention drugs can be conducted. These 
include nebuliser use, and vaccinations, in particular, the pneumococcal, influenza and 
the combination of pneumococcal/influenza vaccinations. These have been 
documented by number of claims and cost of claims in each annual report. Table 7 
documents that nebuliser use has increased on nearly an annual basis from 47,775 
claims in 2005 to 88,031 claims in 2015. The cost per nebuliser use was €36 in 2005 
and this steadily rose to €45 in 2008 and 2009 but since then has steadily decreased in 
cost from 2010 (€43) onwards. In 2015 it cost €37 for nebuliser use in the PCRS 
scheme. This is approximately the same as the 2005 value. A similar trend has been 
seen in the cost of the pneumococcal vaccination. In 2005, the price per vaccination 
was €34 this rose each year to €42 in 2010 then steadily declined to €28 in 2015. Again 
less than 2005 values. This same trend has been replicated in both the influenza 
vaccination and the combination of the pneumococcal /influenza vaccination. The cost 
per vaccination was €33 and €50 respectively in 2005 rising to €42 and decreasing to 
€15 and €42 in 2015 respectively, less than 2005 values. Management of respiratory 
drugs and prevention interventions have decreased in cost from 2009 onwards, with 
an exception in 2012, which did not exceed 2009 levels. 
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Table 7: 2005-2015 PCRS Schemes: Analysis of Special Items of Service. – Related 
to Respiratory Disease  
 
Source: Primary Care Reimbursement Service (PCRS): Statistical Analysis of Claims and Reimbursements 2005-2015. 
 
In summary, firstly, during the period that was under review, respiratory medicine 
expenditure has been less than ten percent of all PCRS expenditure. Secondly, the 
highest expenditure were drugs for obstructive pulmonary disorder and they are the 
most frequently prescribed respiratory medicine ATC Class.  Thirdly, that the B2 
stimulants and corticoids combination group have the highest expenditure out of the 
drugs for OPD, and the B2 stimulants group are the most frequently dispensed. Finally, 
preventative measures are taken to combat respiratory disease such as vaccinations 
and nebuliser use. The cost of these items have decreased over the review period. 
Nebuliser   and the influenza vaccination use has increased over this time and the 
pneumococcal and influenza/ pneumococcal combination vaccinations has decreased.
NUMBER OF CLAIMS 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
NEBULISER 47,775         50,496         49,863         53,715           50,945           57,691           65,669           74,203         74,346       80,542       88,031       
PNEUMONOCOCCAL
 VACCINATION 20,337         12,339         12,264         16,307           14,588           14,332           17,201           16,711         16,195       14,353       14,950       
INFLUENZA
VACCINATION 299,094       299,769       320,634       329,030        349,890         371,659         401,614        366,166       372,694     375,660     386,716     
PNEUMONOCOCCAL/
INFLUENZA
VACCINATION 23,885         16,286         14,829         17,021           13,482           14,123           15,168           13,119         12,142       10,324       9,354          
COST OF CLAIMS €
NEBULISER 1,726,807   2,139,503   2,215,589   2,454,626     2,334,488     2,493,436     2,631,021     2,973,263   2,866,126 2,985,832 3,275,709 
PNEUMONOCOCCAL
 VACCINATION 699,646       474,463       494,740       671,109        625,251         612,650         637,802        477,029       461,619     409,133     426,075     
INFLUENZA
VACCINATION 9,989,318   11,582,655 13,006,903 13,481,357  14,961,300   15,887,673   15,940,542  10,458,833 5,780,058 5,642,331 5,800,864 
PNEUMONOCOCCAL/
INFLUENZA
VACCINATION 1,204,778   942,133       901,338       1,047,577     863,658         905,535         885,028        562,183       519,158     441,374     399,884     
COST PER ITEM €
NEBULISER 36.14 42.37 44.43 45.70 45.82 43.22 40.06 40.07 38.55 37.07 37.21
PNEUMONOCOCCAL
VACCINATION 34.40 38.45 40.34 41.15 42.86 42.75 37.08 28.55 28.50 28.51 28.50
INFLUENZA
VACCINATION 33.40 38.64 40.57 40.97 42.76 42.75 39.69 28.56 15.51 15.02 15.00
PNEUMONOCOCCAL/
INFLUENZA
VACCINATION 50.44 57.85 60.78 61.55 64.06 64.12 58.35 42.85 42.76 42.75 42.75
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4.3.  Objective 3: Estimation of percentage of private respiratory medicines 
expenditure. 
To set the percentage the sell-out data23 (described previously) provided by 
QuintilesIMS Ltd was used. In this section the total drugs for OPD dispensed per 
scheme are reviewed as a percentage. Each year or part thereof has been reviewed to 
analyse any trends that may occur. Graph 12 below shows that the sell-out data is 
consistently dispensed through each time bracket. 
Graph 12. Respiratory drug distribution per scheme. Percentage. 
 
The GMS and GMS repeat scheme (the GMS repeat scheme is where a doctor may 
prescribe a maximum of three months’ treatment for a medical card patient on a 
separate repeat GMS prescription form. The prescriber must write ‘repeat x 2’ on the 
top copy. The repeat GMS prescription form is a six-part form, two parts to each 
dispensing. Each of the instalments can be dispensed at any pharmacy. When a 
pharmacist had dispensed the first month’s instalment they keep the bottom two 
copies, stamp the top copy and write the date of dispensing on it and return the 
remaining copies to the patient. The same procedure applies on the second and third 
dispensing25) accounted for 70-71% since July 2014 to June 2016.The DPS 
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accounted for 15-16%, the LTI accounted for 0%, and all other schemes accounted 
for 1% during the same time period. The dispensing of respiratory drugs to the private 
group are between 12-13% for the time period July 2014 to June 2016. 
Since this sell out data became available there is a consistent trend in the percentage 
of units dispensed that are allocated to the relevant PCRS and private schemes.  Most 
drugs for OPD are dispensed to patients in the GMS and GMS repeat scheme, 
followed by the DPS and private schemes. Graph 12 illustrates that in total 87% of 
drugs to treat OPD in the community are dispensed through a Government funded 
scheme and 13% are paid for privately. Though this data is demonstrated for the 
medicines in ATC class – drugs for OPD, which has by far the largest expenditure, 
Graph 7 illustrates that the same trends have been followed for the other respiratory 
medicines classes, apart from the Hi tech respiratory medicines. These medicines are 
not licenced to treat the respiratory diseases that are involved in the chronic disease 
management programmes. The assumption is therefore made that 87% of respiratory 
medicines that are dispensed in the retail pharmacy are funded by a public 
Government scheme. 
In summary, 87% of respiratory medicines that are dispensed in retail pharmacy are 
funded by a public Government scheme and 13% are funded privately. 
 
4.4.  Objective 4: Calculation to determine the cost of funding respiratory 
medicines through public schemes. 
To estimate cost a scenario analysis (table 8) using two different approaches was 
used. 
Scenario 1. In objective three,   section 4.3, an analysis was conducted and 
determined that 87% of respiratory medicines in the primary setting are funded by 
the Government through its public schemes. Thus 13% of respiratory medicines are 
funded privately. Scenario 1 in Table 8, demonstrates how much it would cost the 
State to pay for respiratory medicines in 2015 if 87% was used as the proportion of 
public expenditure on respiratory medicine. A calculation was then conducted to 
determine the private expenditure on respiratory medicines.  In 2015, the private 
spend equates to €20.2m. Using these assumptions, if the Government were to 
undertake to cover the cost of publically funding all respiratory medicines, the total 
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cost in 2015 would be €155m of which €135.25m is already funded by the 
Government. 
 
Scenario 2 In this scenario a literature review was undertaken to ascertain if there 
was any published information informing on what percentage of expenditure on 
medicines are paid for publicly and privately. The Irish Pharmaceutical Health care 
Association published on their website that 80% of medicines are paid for by the 
State in Ireland 26.  Using this data, Scenario two in table 8 demonstrates how much 
it would cost for the State to pay for respiratory medicines in 2015, if this percentage 
ratio was used. The public cost was €135.25m in 2015 and if that equates to 80% of 
all expenditure in the public schemes on respiratory medicines, then 20% equates to 
private spend which is €33.8m. Adding the private cost to the public expenditure 
would result in a value of €169m for the Government to cover the costs of all 
respiratory medicines in 2015, of which they already provided €135.25m.  
.  
 
Table 8. Scenario Analysis.  Calculation of cost to Government to fund all respiratory 
medicine expenditure. 2015. €m. 
 
 
 
 
 
 
 
 
 
 
 
Source: Primary Care Reimbursement Service (PCRS): Statistical Analysis of Claims and Reimbursements2015.  GMS 
=General Medical Service; DPS=Drug Payment Scheme; LTI=Long Term Illness Scheme; RESP = Respiratory. 
 
Scenario 1. 87%: €m Scenario 2. 80%: €m 
    
87%  Public 
Total  Resp Spend 
 135.25 
80%  Public 
Total Resp Spend 
 135.25 
13% Private 
Total Resp Spend 
 20.20 
20% Private 
Total Resp Spend 
 33.80 
Total Cost of 
Publically funding 
Resp Spend 155 
Total cost of Publically 
funding Resp Spend 169 
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In conclusion, using these two scenarios, the total cost to the State to provide all 
respiratory medicines through public schemes could range from €155m to €169m of 
which they are already financing €135.25m (2015 figures). The extra cost in order to 
provide all respiratory medicines through public schemes could range from between 
€20.2m to €33.8m.  As respiratory disease are chronic diseases and some are part of 
the chronic disease management programmes this extra cost could be paid through 
the LTI scheme. This could result in the removal of an adherence barrier, i.e. cost of 
medications. This aligns with the Governments policy on chronic disease 
management, which endeavours to increase adherence of chronic disease medicines 
(amongst other initiatives) to provide best outcomes for patients and most effective 
use of finite resources.  
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 Section 5.  Conclusions 
The aim of this research paper was to conduct a review of respiratory medicine 
expenditure in Ireland from 2005-2015. Four objectives were set. 
Objective 1. To review expenditure on all PCRS medicines from 2005-2015.  
Objective 2. To review expenditure on all respiratory medicine in the PCRS from 
2005-2015.  
Objective 3. To estimate what percentage of expenditure on respiratory medicines is 
allocated to private funding.  
Objective 4. To calculate how much the Government would have to spend in order 
to cover the costs of respiratory medicines for all patients. 
This research showed that total PCRS expenditure on all medicines have been 
decreasing in recent years with 2015 figures being less than expenditure in 2006. 
Most expenditure is on the GMS scheme.  
Respiratory medicines expenditure has always been below 10% of total PCRS spend. 
Though the actual respiratory medicine spend has decreased in expenditure over the 
eleven year period, it has not decreased as much as the total medicines expenditure 
in the PCRS, thereby increasing in percentage terms.  
The most frequently prescribed class and also the highest expenditure was allocated 
to Drugs to treat OPD, these are the most commonly used class to treat respiratory 
disease. 
 B2 stimulants and corticoids combination class have the highest expenditure out of 
the drugs for OPD, and the B2 stimulants class are the most frequently dispensed. 
Preventative measures are taken to combat respiratory disease such as vaccinations 
and nebuliser use. The cost of these items have decreased, nebuliser   and influenza 
vaccination use has increased over this period whilst the pneumococcal and 
influenza/pneumococcal combination vaccinations have decreased. 
87% of drugs to treat OPD are dispensed publicly and 13% privately. Though this 
data demonstrated using the drugs for OPD class, the assumption was made that this 
equates to the same for all respiratory medicines. 
A scenario analysis was conducted, in which in scenario 1 an 87% public spend was 
assumed. The private spend equates to €20.2m. The total cost in 2015 would be 
€155m of which €135.25m is already funded by the Government. Scenario 2 assumed 
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an 80% public spend equating to €135.25m in 2015 and 20% private spend of 
€33.8m. Total State cost of €169m.  The extra cost to the State could range from 
between €20.2m to €33.8m, in order to provide all respiratory medicines through 
public schemes. This extra cost could be paid through the LTI scheme. 
To effectively manage resources, the State has introduced a policy to implement 
chronic disease management programmes. Some respiratory diseases are part of this 
programme. By managing patients in the community the aim is to increase adherence 
to medicines and offset the costs of emergency hospital admissions amongst other 
cost effective measures. If the State paid for the total cost of respiratory medicines, 
which from this research could range from an extra €20.2m to €33.8m on the LTI 
scheme, then they would be removing an adherence barrier and be supporting their 
overall strategy of effectively managing a chronic disease programme with the 
advantage of the long term financial benefits.
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Appendix. 
 
Appendix i) Supplementary Tables. 
 
 
Table 1: Description of Community Health Schemes. 
General 
Medical 
Services. 
GMS. 
Persons who are unable without undue hardship to arrange general 
practitioner medical and surgical services for themselves and their 
dependants are eligible for the GMS Scheme. Drugs, medicines and 
appliances approved under the Scheme are provided through Community 
Pharmacists. In most cases the GP gives a completed prescription form to 
an eligible person, who takes it to any Pharmacy that has an agreement 
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Source: Primary Care Reimbursement Service (PCRS): Statistical Analysis of Claims and Reimbursements 2015.
with the Health Service Executive to dispense drugs, medicines and 
appliances on presentation of GMS prescription forms. In rural areas a 
small number of GPs hold contracts to dispense drugs and medications to 
GMS cardholders who opt to have their medicines dispensed by him/her 
directly. All GMS claims are processed and paid by the Primary Care 
Reimbursement Service. Since the 1st October 2010, an eligible person 
who is supplied a drug, medicine or medical or surgical appliance on the 
prescription of a Registered Medical Practitioner, Registered Dentist or 
Registered Nurse Prescriber, is charged a prescription charge by the 
Community Pharmacy Contractor, currently €2.50 per item subject to a 
limit of €25 per family per month (effective 1st December 2013). The 
prescription charge is recouped by the HSE from the Pharmacist 5.  
 
Drugs Payment 
Scheme. 
DPS. 
The Drugs Payment Scheme (DPS) provides for payment to the Pharmacist 
for the supply of medicines to individuals and families where the threshold 
of €144, effective from 1st January 2013, has been exceeded in a calendar 
month. In order to avail of the Drugs Payment Scheme a person or family 
must register for the Scheme with the HSE PCRS. Drugs, medicines and 
appliances currently reimbursable under the Scheme are listed on the HSE 
website. Other items which were reimbursable under the Drug Cost 
Subsidisation Scheme and Refund of Drugs Scheme continue, in certain 
circumstances, to be reimbursable under the Drugs Payment Scheme 5 
Long Term 
Illness Scheme. 
LTI. 
on approval by the Health Service Executive, persons who suffer from one 
or more of a schedule of illnesses are entitled to obtain, without charge, 
irrespective of income, necessary drugs/medicines and/or appliances under 
the LTI Scheme 5 
High Tech 
Arrangements. 
HTD. 
Arrangements are in place for the supply and dispensing of High Tech 
medicines through Community Pharmacists. Such medicines are generally 
only prescribed or initiated in hospital and would include items such as 
anti-rejection drugs for transplant patients or medicines used in 
conjunction with chemotherapy or hormonal therapy. The medicines are 
purchased by the Health Service Executive and supplied through 
Community Pharmacists for which Pharmacists are paid a patient care fee. 
The cost of the medicines and patient care fees are paid by the Primary 
Care Reimbursement Service. 
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Table 4a:2005-2015 PCRS Schemes: Respiratory System: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical 
Classification. Ingredient Cost. 
 
Source: Primary Care Reimbursement Service (PCRS): Statistical Analysis of Claims and Reimbursements 2005-2015. GMS = General Medical Service; DPS=Drug Payment Scheme; LTI=Long Term Illness Scheme; 
HTD= Hi Tech Drugs Scheme. 
 
 
Table 4b:2005-2015 PCRS Schemes: Respiratory System: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical 
Classification. Ingredient Cost. Continued.   
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2005 63,292,283          27,206,227          324,411               -                      90,822,921          2,118,399            1,751,043            21,003                 3,890,445            19,931                 5,792                   157                      25,880                 57,823,822          24,080,005          284,282               82,188,109          
2006 71,957,313          30,452,666          357,439               3,310,475            106,077,893        2,439,052            1,975,379            22,166                 4,436,597            19,368                 6,382                   76                        25,826                 65,714,346          26,847,211          313,826               92,875,383          
2007 80,591,553          33,368,619          386,751               3,683,511            118,030,434        2,671,242            2,120,224            20,271                 4,811,737            21,778                 7,837                   89                        29,704                 73,822,405          29,462,482          344,563               103,629,450        
2008 86,217,131          33,552,453          404,830               3,983,645            124,158,059        2,965,692            2,151,701            21,444                 5,138,837            22,476                 7,166                   122                      29,764                 78,998,344          29,675,007          349,708               109,023,059        
2009 98,264,490          33,158,341          443,749               4,286,257            136,152,837        3,340,128            1,979,040            19,107                 5,338,275            26,803                 6,109                   273                      33,185                 90,480,098          29,618,540          363,755               120,462,393        
2010 95,767,539          27,440,182          356,716               4,072,793            127,637,230        332,698               1,505,733            13,388                 1,851,819            24,057                 3,770                   92                        27,919                 88,123,366          24,749,324          256,210               113,128,900        
2011 92,979,263          23,840,546          311,561               3,823,383            120,954,753        2,981,353            1,136,667            9,703                   4,127,723            26,083                 3,119                   96                        29,298                 85,908,631          21,796,022          197,540               107,902,193        
2012 98,412,774          21,705,902          315,295               4,047,173            124,481,144        3,522,629            1,074,249            9,815                   4,606,693            27,741                 2,742                   63                        30,546                 90,594,829          19,827,948          181,310               110,604,087        
2013 92,032,133          16,954,462          309,951               25,579,372          134,875,918        3,750,217            909,824               10,422                 4,670,463            27,437                 2,346                   63                        29,846                 84,268,287          15,436,820          163,703               99,868,810          
2014 90,121,510          15,482,059          414,422               32,616,923          138,634,914        4,283,524            962,973               16,722                 5,263,219            23,641                 1,766                   38                        25,445                 82,097,475          13,976,503          233,100               96,307,078          
2015 92,107,418          15,655,216          474,533               34,136,127          142,373,294        4,774,176            1,050,201            17,364                 5,841,741            20,700                 1,707                   33                        22,440                 83,545,262          14,044,655          272,546               97,862,463          
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Source: Primary Care Reimbursement Service (PCRS): Statistical Analysis of Claims and Reimbursements 2005-2015. GMS = General Medical Service; DPS=Drug Payment Scheme; LTI=Long Term Illness Scheme; 
HTD= Hi Tech Drugs Schem
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2005 1,404,147            295,327               5,813                   1,705,287            1,902,221            1,072,590            13,156                 2,987,967            23,763                 1,470                   0 0 25,233                 0
2006 1,516,352            331,405               5,443                   1,853,200            2,245,256            1,290,777            15,928                 3,551,961            22,759                 1,512                   0 0 24,271                 3,310,475            
2007 1,566,293            338,785               4,579                   1,909,657            2,491,471            1,438,019            17,249                 3,946,739            18,364                 1,272                   0 0 19,636                 3,683,511            
2008 1,539,813            303,592               12,556                 1,855,961            2,676,784            1,413,979            21,000                 4,111,763            14,022                 1,008                   0 0 15,030                 3,983,645            
2009 1,396,577            224,557               41,588                 1,662,722            3,009,095            1,329,459            19,026                 4,357,580            11,789                 636                      0 0 12,425                 4,286,257            
2010 1,250,716            161,925               72,856                 1,485,497            3,031,589            1,019,087            14,260                 4,064,936            5,113                   343                      0 0 5,456                   4,072,793            
2011 1,485,851            168,430               93,860                 1,748,141            2,573,906            736,182               10,452                 3,320,540            3,439                   126                      0 0 3,565                   3,823,383            
2012 1,574,653            150,858               112,542               1,838,053            2,692,518            650,070               11,565                 3,354,153            404                      35                        0 0 439                      4,047,173            
2013 1,492,670            127,360               122,118               1,742,148            2,493,504            478,112               13,645                 2,985,261            18                        0 0 21,362,464          21,362,482          4,216,908            
2014 1,368,040            125,113               146,589               1,639,742            2,348,830            415,704               17,973                 2,782,507            0 0 0 28,405,929          28,405,929          4,210,994            
2015 1,339,161            131,612               165,135               1,635,908            2,428,119            427,041               19,455                 2,874,615            0 0 0 29,806,775          29,806,775          4,329,352            
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Table 5a:2005-2015 PCRS Schemes: Respiratory System: Distribution of Medicines and Appliances by Anatomical Therapeutic 
Chemical Classification. Prescribing Frequency. 
Source: Primary Care Reimbursement Service (PCRS): Statistical Analysis of Claims and Reimbursements 2005-2015. GMS = General Medical Service; DPS=Drug Payment Scheme; LTI=Long Term 
Illness Scheme; HTD= Hi Tech Drugs Scheme 
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2005 2,745,138 1,086,842 13,686      -            3,845,666 183,748    131,181    1,517        316,446    8,757        2,575        27             11,359      2,060,368 795,004    9,775        2,865,147 
2006 2,975,130 1,208,575 14,464      3,658        4,201,827 207,516    147,289    1,644        356,449    8,503        2,797        29             11,329      2,211,224 871,350    10,253      3,092,827 
2007 3,239,879 1,335,221 14,771      3,849        4,593,720 232,317    163,744    1,600        397,661    9,564        3,509        37             13,110      2,386,606 954,072    10,668      3,351,346 
2008 3,524,959 1,366,662 16,199      4,170        4,911,990 266,010    173,809    1,729        441,548    10,376      3,352        48             13,776      2,577,213 973,503    11,429      3,562,145 
2009 3,750,446 1,281,721 16,074      4,437        5,052,678 298,437    166,948    1,569        466,954    11,595      2,825        40             14,460      2,733,416 914,645    11,583      3,659,644 
2010 4,067,914 1,057,441 13,262      4,359        5,142,976 352,159    143,473    1,277        496,909    11,303      1,783        33             13,119      2,939,392 750,823    9,039        3,699,254 
2011 4,337,703 979,953    11,916      4,595        5,334,167 393,155    135,284    1,123        529,562    12,256      1,499        29             13,784      3,084,042 690,690    7,604        3,782,336 
2012 4,785,070 910,661    11,968      4,918        5,712,617 444,843    123,806    1,152        569,801    13,381      1,340        23             14,744      3,384,351 641,161    7,439        4,032,951 
2013 4,780,296 757,892    12,353      6,264        5,556,805 472,301    105,625    1,258        579,184    13,215      1,144        19             14,378      3,344,201 527,514    7,526        3,879,241 
2014 4,717,035 698,842    17,058      6,584        5,439,519 478,737    97,171      1,767        577,675    11,458      855           13             12,326      3,309,962 485,498    11,071      3,806,531 
2015 4,807,848 713,622    20,471      7,972        5,549,913 495,103    100,051    1,777        596,931    9,963        829           9               10,801      3,373,497 494,797    13,358      3,881,652 
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Table 5b: 2005-2015 PCRS Schemes: Respiratory System: Distribution of Medicines and Appliances by Anatomical Therapeutic 
Chemical Classification. Prescribing Frequency. Continued.  
Source: Primary Care Reimbursement Service (PCRS): Statistical Analysis of Claims and Reimbursements 2005-2015.GMS = General Medical Service; DPS=Drug Payment Scheme; LTI=Long Term 
Illness Scheme; HTD= Hi Tech Drugs Scheme
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2005 273,563    53,210      873           327,646    217,649    104,804    1,494        323,947    1,053        68             0 0 1,121        -            
2006 291,462    60,258      826           352,546    255,476    126,809    1,712        383,997    949           72             0 0 1,021        3,658        
2007 326,126    67,233      693           394,052    284,523    146,605    1,773        432,901    743           58             0 0 801           3,849        
2008 351,277    64,238      876           416,391    319,518    151,715    2,117        473,350    565           45             0 0 610           4,170        
2009 352,058    51,593      1,088        404,739    354,500    145,683    1,794        501,977    440           27             0 0 467           4,437        
2010 355,115    38,174      1,457        394,746    409,760    123,176    1,456        534,392    185           12             0 0 197           4,359        
2011 392,586    36,901      1,788        431,275    455,570    115,572    1,372        572,514    94             7               0 0 101           4,595        
2012 415,711    32,781      2,078        450,570    526,772    111,571    1,276        639,619    12             2               0 0 14             4,918        
2013 380,431    26,051      2,385        408,867    570,147    97,558      1,165        668,870    1               -            0 1,192        1,193        5,072        
2014 335,676    23,197      3,070        361,943    581,202    92,121      1,587        674,910    0 0 0 1,576        1,576        5,008        
2015 327,459    23,140      3,629        354,228    601,826    94,805      1,698        698,329    0 0 0 1,976        1,976        5,996        
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Appendix ii) Supplemental Graphs. 
Graph 10 Respiratory ATC Classification units per scheme. Jan 2015-Dec2015. 
 
Graph 11. Respiratory ATC Classification units per scheme. Jan 2016-Jun2016. 
 
 
 
